NCT02920229View on ClinicalTrials.gov

68Ga-PSMA HBED-PET/CT in the Evaluation of the Biochemical Relapse in Patients With a History of Prostate Cancer Radically Treated

NACompletedINTERVENTIONAL
Enrollment

1,230

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

October 9, 2020

Study Completion Date

October 9, 2020

Conditions
68Ga-PSMA HBED-PET/CTProstate Cancer
Interventions
DRUG

68Ga- PSMA

100-200 MBq of 68Ga-PSMA will be injected intravenously prior to perform the PET/CT

Trial Locations (1)

47014

Irst Irccs, Meldola

All Listed Sponsors
lead

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

OTHER

NCT02920229 - 68Ga-PSMA HBED-PET/CT in the Evaluation of the Biochemical Relapse in Patients With a History of Prostate Cancer Radically Treated | Biotech Hunter | Biotech Hunter